CVSIOTCPharmaceutical PreparationsFiscal year ends December 31
CV Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.01−0.00 (-21.13%)
Close on Oct 19, 2026
- Market cap
- $2.30M
- P/E (TTM)
- –
- Dividend yield
- –
CV Sciences, Inc. revenue by segment
By business segment
| Revenue | TTM Q3 22 | TTM Q2 22 | TTM Q1 22 | TTM Q4 21 | TTM Q3 21 | TTM Q2 21 | TTM Q1 21 | TTM Q4 20 | TTM Q3 20 | TTM Q2 20 | TTM Q1 20 | TTM Q4 19 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumer Products Segment | $17.31M | $18.66M | $19.65M | $20.05M | $20.28M | $20.74M | $21.00M | $24.43M | $28.56M | $35.60M | $47.06M | $53.70M | 100.0% | -14.7% |
| Specialty Pharmaceutical Segment | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | 0.0% | – |
| Operating income | TTM Q3 22 | TTM Q2 22 | TTM Q1 22 | TTM Q4 21 | TTM Q3 21 | TTM Q2 21 | TTM Q1 21 | TTM Q4 20 | TTM Q3 20 | TTM Q2 20 | TTM Q1 20 | TTM Q4 19 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specialty Pharmaceutical Segment | -$5.35M | -$5.65M | -$5.73M | -$5.79M | -$689.00K | -$697.00K | -$1.24M | -$2.38M | -$3.19M | -$4.01M | -$4.38M | -$3.82M | +676.9% |
| Consumer Products Segment | -$8.21M | -$10.01M | -$11.12M | -$12.66M | -$18.38M | -$18.54M | -$19.15M | -$20.22M | -$17.28M | -$15.09M | -$8.81M | -$13.42M | -55.3% |
By product or service
By region
From the segment and revenue-disaggregation notes of CV Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.